Commentary
Video
Outlining Phase 3 VITALIZE and MOBILIZE Trials of Riliprubart in CIDP: Luis Querol, MD, PhD
Author(s):
The neurologist at the Hospital de la Santa Creu, in Barcelona, Spain, outlined the goals and significance of the VITALIZE and MOBILIZE phase 3 trials evaluating riliprubart in standard-of-care and treatment-refractory CIDP populations. [WATCH TIME: 3 minutes]
WATCH TIME: 4 minutes
"These phase 3 trials are ambitious—one targets an underserved population, and the other challenges the standard of care for the first time in CIDP."
An investigational agent, riliprubart (Sanofi) tests the theory whether complement-inhibiting action can have significant therapeutic effect on patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The therapy has shown promise in a phase 2 trial (NCT04658472), with patients experiencing improvements in patient-reported fatigue and quality-of-life measures across a 76-week treatment period. These effects, seen in refractory patients and those on standard-of-care therapies in addition to riliprubart, further highlighted the potential this agent may bring to patients.
A bevy of presentations regarding riliprubart were presented at the 2025 Peripheral Nerve Society (PNS) Annual Meeting, held May 17-20, in Edinburgh, Scotland. Among them included subgroup analyses, biomarker data on the drug’s impact on neurofilament light levels, and the design of 2, phase 3 trials set to test the drug’s efficacy and safety. The studies, dubbed VITALIZE (NCT06290128) and MOBILIZE (NCT06290141), were launched in 2024 and are actively enrolling participants across 28 countries in North and South America, Europe, and Asia.
Treatment duration in both trials is 48 weeks: 24-week double-blind period (Part A), followed by a 24-week open-label period (Part B). To better understand the details behind this trial, NeurologyLive sat down with site investigator Luis Querol, MD, PhD, a neurologist at the Hospital de la Santa Creu, in Barcelona, Spain. Querol, a study author for the phase 2 trial, discussed the rationale behind each trial, how they differ, and the main goals the study investigators are looking to achieve. Furthermore, he also touched on the significance of VITALIZE being one of the first trials to directly compare a novel therapy to intravenous immunoglobulins (IVIg), the long-standing standard of care for CIDP.
Click here for more PNS 2025 coverage.
